Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC
NCT05110196Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capmatinib in non-small cell lung carcinoma (NSCLC), sponsored by Novartis. Primary endpoints: Treatment-Emergent Adverse Events up to 7 months, Dose Modifications up to 6 months and 1 more. Started Sep 2022; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05110196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110196.